JPWO2022097634A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022097634A5
JPWO2022097634A5 JP2022560780A JP2022560780A JPWO2022097634A5 JP WO2022097634 A5 JPWO2022097634 A5 JP WO2022097634A5 JP 2022560780 A JP2022560780 A JP 2022560780A JP 2022560780 A JP2022560780 A JP 2022560780A JP WO2022097634 A5 JPWO2022097634 A5 JP WO2022097634A5
Authority
JP
Japan
Prior art keywords
cas
cyclic
sting agonist
fasl
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560780A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022097634A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/040374 external-priority patent/WO2022097634A1/ja
Publication of JPWO2022097634A1 publication Critical patent/JPWO2022097634A1/ja
Publication of JPWO2022097634A5 publication Critical patent/JPWO2022097634A5/ja
Pending legal-status Critical Current

Links

JP2022560780A 2020-11-04 2021-11-02 Pending JPWO2022097634A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020184442 2020-11-04
PCT/JP2021/040374 WO2022097634A1 (ja) 2020-11-04 2021-11-02 血管新生依存性疾患治療に使用される医薬用組成物

Publications (2)

Publication Number Publication Date
JPWO2022097634A1 JPWO2022097634A1 (cg-RX-API-DMAC7.html) 2022-05-12
JPWO2022097634A5 true JPWO2022097634A5 (cg-RX-API-DMAC7.html) 2025-04-11

Family

ID=81457183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560780A Pending JPWO2022097634A1 (cg-RX-API-DMAC7.html) 2020-11-04 2021-11-02

Country Status (2)

Country Link
JP (1) JPWO2022097634A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022097634A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268350B1 (en) * 1997-10-23 2001-07-31 Biocrystal Ltd. Polynucleotides for inhibiting metastasis and tumor cell growth
DK1771206T3 (en) * 2004-05-05 2018-05-22 Silence Therapeutics Gmbh LIPIDS, LIPID COMPLEXES AND USE THEREOF

Similar Documents

Publication Publication Date Title
Gao et al. Targeted mRNA nanoparticles ameliorate blood–brain barrier disruption postischemic stroke by modulating microglia polarization
Li et al. Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape
Huang et al. Unlocking the therapeutic applicability of LNP-mRNA: chemistry, formulation, and clinical strategies
Havaei et al. Pseudomonas exotoxin-based immunotoxins: over three decades of efforts on targeting cancer cells with the toxin
US7354579B2 (en) Method of treating cancer with a VEGF antagonist and an anti-proliferative agent
Kafle et al. Development of thermally stable mRNA-LNP delivery systems: current progress and future prospects
JP2025066807A (ja) 生体直交型組成物
Zhu et al. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles
Qian et al. Hyaluronan reduces cationic liposome-induced toxicity and enhances the antitumor effect of targeted gene delivery in mice
JP5704788B2 (ja) 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ
Koga et al. Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenografts
Xu et al. Inhaled RNA therapeutics for obstructive airway diseases: recent advances and future prospects
JPH07316074A (ja) 腫瘍および炎症性疾患を選択的に治療するために用いられる、壊死を引き起こす物質と、壊死により活性化される物質との組み合わせ
McGonigle et al. Neuropilin-1 drives tumor-specific uptake of chlorotoxin
Zhang et al. Prevent and reverse metabolic dysfunction-associated steatohepatitis and hepatic fibrosis via mRNA-mediated liver-specific antibody therapy
US6660264B1 (en) Treatment of intracellular infection
Suzuki et al. Differences and similarities of the intravenously administered lipid nanoparticles in three clinical trials: potential linkage between lipid nanoparticles and extracellular vesicles
Liu et al. Environmentally self-adaptative nanocarriers suppress glioma proliferation and stemness via codelivery of shCD163 and doxorubicin
TW201705977A (zh) 作為治療疫苗之奈米顆粒
Han et al. Enhancing cardioprotection through neutrophil‐mediated delivery of 18β‐glycyrrhetinic acid in myocardial ischemia/reperfusion injury
Shetab Boushehri et al. Challenges of using lipopolysaccharides for cancer immunotherapy and potential delivery-based solutions thereto
Ning et al. Gene reprogramming armed macrophage membrane-camouflaged nanoplatform enhances bionic targeted drug delivery to solid tumor for synergistic therapy
Wei et al. Cell-and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy
Song et al. Microenvironments‐targeted nanomaterials for atherosclerosis therapy
Zhou et al. Self-assembled glycopeptide as a biocompatible mRNA vaccine platform elicits robust antitumor immunity